Azzurra Irelli

11PUBLICATIONS
26CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer geneticsPsychosocial aspects of childbirth and perinatal mental healthMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Mar 28, 2026
Anthracycline-Free Neoadjuvant Pertuzumab-Trastuzumab-Taxane in Patients with HER2-Positive Early Breast Cancer: Hormone Receptor Status as a Key Determinant of Pathological Complete Response.

Azzurra Irelli, Tina Sidoni, Francesco Pavese

|Aug 04, 2025
Trastuzumab deruxtecan in patients with bone metastases from HR+/HER2-low breast cancer: efficacy enhanced by denosumab.

Azzurra Irelli, Leonardo Valerio Patruno, Katia Cannita

|Dec 17, 2024
Tolerability and Preliminary Outcomes of Adjuvant T-DM1 in HER2-Positive Breast Cancer After Neoadjuvant Therapy: The ATD Study.

Eriseld Krasniqi, Lorena Filomeno, Teresa Arcuri

|Apr 27, 2024
Role of Breast Cancer Risk Estimation Models to Identify Women Eligible for Genetic Testing and Risk-Reducing Surgery.

Azzurra Irelli, Leonardo Valerio Patruno, Sofia Chiatamone Ranieri

|Jan 23, 2024
Takotsubo Syndrome during Pertuzumab and Trastuzumab Therapy for HER2-Positive Metastatic Breast Cancer.

Azzurra Irelli, Laura Ceriello, Leonardo Valerio Patruno

|Mar 29, 2023
Role of the Molecular Tumor Board for the Personalized Treatment of Patients with Metastatic Breast Cancer: A Focus on the State of the Art in Italy.

Azzurra Irelli, Sofia Chiatamone Ranieri, Daniela Di Giacomo

Pageof 2

Frequent Collaborators

3 joint publications

Lia Ginaldi

2 joint publications

Alessio Cortellini

2 joint publications

Maria Maddalena Sirufo

2 joint publications

Massimo De Martinis